Insomnia - Pipeline Review, H1 2018

  • ID: 4515992
  • Drug Pipelines
  • 110 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Athenex Inc
  • Evotec AG
  • Icure Pharmaceutical Inc
  • Intec Pharma Ltd
  • Leading BioSciences Inc
  • Sage Therapeutics Inc
  • MORE
Insomnia - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Insomnia - Pipeline Review, H1 2018, provides an overview of the Insomnia (Central Nervous System) pipeline landscape.

Insomnia is a sleep disorder that is characterized by difficulty falling and/or staying asleep. Symptoms include difficulty falling asleep at night, irritability, depression or anxiety, tension headaches and distress in the stomach and intestines. Risk factors include age, mental health disorder, stress and shift working.

Report Highlights:

This latest Pharmaceutical and Healthcare disease pipeline guide pipeline guide Insomnia - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Insomnia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Insomnia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Insomnia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 10, 6, 9, 5 and 1 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 3 molecules, respectively.

Insomnia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researechers' proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Insomnia (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Insomnia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Insomnia (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Insomnia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Insomnia (Central Nervous System)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Insomnia (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Insomnia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Athenex Inc
  • Evotec AG
  • Icure Pharmaceutical Inc
  • Intec Pharma Ltd
  • Leading BioSciences Inc
  • Sage Therapeutics Inc
  • MORE
Introduction

Report Coverage

Insomnia - Overview

Insomnia - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Insomnia - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Insomnia - Companies Involved in Therapeutics Development

Alexza Pharmaceuticals Inc

Athenex Inc

Eisai Co Ltd

Evotec AG

Grupo Ferrer Internacional SA

Heptares Therapeutics Ltd

Icure Pharmaceutical Inc

Idorsia Ltd

Intec Pharma Ltd

Intra-Cellular Therapies Inc

Johnson & Johnson

Leading BioSciences Inc

Merck & Co Inc

Neurim Pharmaceuticals Ltd

Reviva Pharmaceuticals Inc

Sage Therapeutics Inc

Shionogi & Co Ltd

Taisho Pharmaceutical Holdings Co Ltd

Yangtze River Pharmaceutical Group

Insomnia - Drug Profiles

(diphenhydramine + lorazepam + zolpidem tartrate) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ACT-541468 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CB-2810 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CY-18 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CY-20 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DORA-12 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DRGT-73 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug for Insomnia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs to Inhibit Angiotensin II Receptor Type 1 for Insomnia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EVT-201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HTL-6641 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JNJ-48816274 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LASSBio-785 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LASSBio-786 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lemborexant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lorediplon - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lumateperone tosylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

melatonin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MK-8133 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MLS-03 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nebivolol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NEO-1940 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NFX-91 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

piromelatine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

S-117957 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SAGE-217 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

seltorexant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Insomnia, Obesity and Treatment Resistant Depression - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate CYP1A2 for Insomnia and Anxiety - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize CB1 and CB2 for Autism, Dermatitis and Insomnia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize Orexin 1 and 2 Receptors for Insomnia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TS-142 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

UCM-765 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

zaleplon - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

zaleplon - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

zolpidem tartrate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

zolpidem tartrate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Insomnia - Dormant Projects

Insomnia - Discontinued Products

Insomnia - Product Development Milestones

Featured News & Press Releases

Dec 06, 2017: Minerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial of Seltorexant (MIN-202) in Patients With Insomnia Disorder

Nov 29, 2017: Australian Regulators Approve Zelda's Insomnia Clinical Trial

Sep 13, 2017: Zelda Therapeutic: Update on Research Programme in Chile

Sep 05, 2017: Minerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial of Seltorexant (MIN-202) as Adjunctive Therapy in Patients with Major Depressive Disorder

Aug 25, 2017: Blake Insomnia Therapeutics Announces Submitting Clinical Trial Application for Phase II Clinical Testing

Jul 28, 2017: ACT-541468 (DORA) meets primary endpoint in Phase 2 program in adult and elderly patients with insomnia

Mar 02, 2017: Blake Insomnia Therapeutics and Sajo Consulting Introduce Clinical Trial Team Members

Feb 06, 2017: Ergomed announces positive Phase II top-line results of co-development partner Ferrer’s Lorediplon for the treatment of insomnia

Jan 17, 2017: Blake Insomnia Therapeutics Seeks Financing for Clinical Trials

Sep 08, 2016: Ergomed Completes Recruitment of Phase IIa Clinical Trial of Lorediplon in Insomnia in Collaboration with co-development Partner Ferrer

Jul 07, 2016: Actelion To Enter Phase II Clinical Development With New Dual Orexin Receptor Antagonist In Patients With Insomnia

Jun 01, 2016: Minerva Neurosciences to Present data on MIN-

Feb 01, 2016: Minerva Neurosciences Announces Top Line Data From MIN-202 Phase I Clinical Study in Japanese Patients

Jan 11, 2016: Minerva Neurosciences Announces Favorable Top Line Results From MIN-202 Phase 2A Clinical Trial in Insomnia Disorder

Dec 16, 2015: Intec Pharma Further Expands Intellectual Property with a New Patent for the Accordion Pill Zaleplon in Europe

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Insomnia, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Insomnia - Pipeline by Alexza Pharmaceuticals Inc, H1 2018

Insomnia - Pipeline by Athenex Inc, H1 2018

Insomnia - Pipeline by Eisai Co Ltd, H1 2018

Insomnia - Pipeline by Evotec AG, H1 2018

Insomnia - Pipeline by Grupo Ferrer Internacional SA, H1 2018

Insomnia - Pipeline by Heptares Therapeutics Ltd, H1 2018

Insomnia - Pipeline by Icure Pharmaceutical Inc, H1 2018

Insomnia - Pipeline by Idorsia Ltd, H1 2018

Insomnia - Pipeline by Intec Pharma Ltd, H1 2018

Insomnia - Pipeline by Intra-Cellular Therapies Inc, H1 2018

Insomnia - Pipeline by Johnson & Johnson, H1 2018

Insomnia - Pipeline by Leading BioSciences Inc, H1 2018

Insomnia - Pipeline by Merck & Co Inc, H1 2018

Insomnia - Pipeline by Neurim Pharmaceuticals Ltd, H1 2018

Insomnia - Pipeline by Reviva Pharmaceuticals Inc, H1 2018

Insomnia - Pipeline by Sage Therapeutics Inc, H1 2018

Insomnia - Pipeline by Shionogi & Co Ltd, H1 2018

Insomnia - Pipeline by Taisho Pharmaceutical Holdings Co Ltd, H1 2018

Insomnia - Pipeline by Yangtze River Pharmaceutical Group, H1 2018

Insomnia - Dormant Projects, H1 2018

Insomnia - Dormant Projects, H1 2018 (Contd..1), H1 2018

Insomnia - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Insomnia, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Alexza Pharmaceuticals Inc
  • Athenex Inc
  • Eisai Co Ltd
  • Evotec AG
  • Grupo Ferrer Internacional SA
  • Heptares Therapeutics Ltd
  • Icure Pharmaceutical Inc
  • Idorsia Ltd
  • Intec Pharma Ltd
  • Intra-Cellular Therapies Inc
  • Johnson & Johnson
  • Leading BioSciences Inc
  • Merck & Co Inc
  • Neurim Pharmaceuticals Ltd
  • Reviva Pharmaceuticals Inc
  • Sage Therapeutics Inc
  • Shionogi & Co Ltd
  • Taisho Pharmaceutical Holdings Co Ltd
  • Yangtze River Pharmaceutical Group
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll